amivantamab + carboplatin + paclitaxel

This combination therapy consists of amivantamab, a fully human bispecific antibody targeting EGFR and MET, administered alongside the chemotherapy agents carboplatin and paclitaxel. In the context of the SWOG Cancer Research Network's Phase II trial (S2307), amivantamab is utilized in its subcutaneous formulation, co-formulated with recombinant human hyaluronidase. Amivantamab works by inhibiting ligand binding, promoting receptor downregulation, and inducing Fc-dependent immune activity such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Carboplatin is a platinum-based antineoplastic agent that causes DNA cross-linking, while paclitaxel is a taxane that stabilizes microtubules, both leading to cell cycle arrest and apoptosis. This triplet regimen is being evaluated for patients with unresectable locally recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have progressed after PD-(L)1 inhibitor therapy.

Brand names

RybrevantParaplatinTaxol

Other names

amivantamab-hyaluronidase + carboplatin + paclitaxelamivantamab + carboplatin + paclitaxel